JPMorgan Chase & Co. Sells 49,046 Shares of Celldex Therapeutics, Inc. $CLDX

JPMorgan Chase & Co. cut its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 21.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 184,775 shares of the biopharmaceutical company’s stock after selling 49,046 shares during the quarter. JPMorgan Chase & Co. owned 0.28% of Celldex Therapeutics worth $4,780,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CLDX. Wellington Management Group LLP lifted its position in Celldex Therapeutics by 10.8% during the third quarter. Wellington Management Group LLP now owns 5,800,003 shares of the biopharmaceutical company’s stock valued at $150,046,000 after purchasing an additional 567,677 shares during the last quarter. Bellevue Group AG increased its holdings in shares of Celldex Therapeutics by 7.6% in the 3rd quarter. Bellevue Group AG now owns 3,557,669 shares of the biopharmaceutical company’s stock worth $92,037,000 after buying an additional 250,100 shares during the last quarter. Commodore Capital LP raised its position in shares of Celldex Therapeutics by 7.8% during the 2nd quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock valued at $70,208,000 after buying an additional 250,000 shares in the last quarter. Eventide Asset Management LLC raised its position in shares of Celldex Therapeutics by 37.1% during the 3rd quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock valued at $48,096,000 after buying an additional 502,909 shares in the last quarter. Finally, Vestal Point Capital LP lifted its holdings in shares of Celldex Therapeutics by 781.0% in the 2nd quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $35,612,000 after acquiring an additional 1,551,354 shares during the last quarter.

Celldex Therapeutics Trading Down 0.6%

Shares of NASDAQ:CLDX opened at $31.06 on Friday. The company has a market capitalization of $2.07 billion, a price-to-earnings ratio of -7.98 and a beta of 1.19. Celldex Therapeutics, Inc. has a 12 month low of $14.40 and a 12 month high of $34.52. The firm’s 50-day moving average is $27.59 and its 200 day moving average is $26.68.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. As a group, equities analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on CLDX shares. The Goldman Sachs Group lifted their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price for the company in a report on Monday, March 23rd. Barclays boosted their target price on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research report on Wednesday, December 17th. Finally, Stifel Nicolaus restated a “buy” rating and set a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $44.45.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.